Rein Therapeutics, Inc.

Rein Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing inhaled therapies for fibrotic and other serious lung diseases. Its pipeline includes LTI-03 for idiopathic pulmonary fibrosis and LTI-01 for lung-related indications, with development activities conducted through clinical research partners and external manufacturing and regulatory support.

0.70

0.70

— Rein Therapeutics, Inc.
%
LTI-030% Inhaled peptide candidate being developed for idiopathic pulmonary fibrosis.
LTI-010% Earlier-stage lung disease product candidate in the company pipeline.
Clinical development services45% Outsourced clinical trial execution, monitoring, and study operations for pipeline programs.
Preclinical and nonclinical development25% Animal studies, toxicology work, and supporting research required before and during trials.
Regulatory and CMC support30% Regulatory consulting, manufacturing, and clinical supply activities tied to development.

Rein Therapeutics does not sell commercial products; its primary counterparties are clinical research organizations,...

  • Clinical research organizationsprimary

    They perform trial management and study execution for LTI-03 and other programs.

  • Manufacturing and development vendorsprimary

    They supply clinical materials, testing, and development support needed for trials.

  • Regulatory authoritiesprimary

    They review safety, toxicology, and clinical data needed to advance candidates.

  • Potential licensing partnerssecondary

    They may acquire or license non-core assets such as oncology programs.

  • Future pulmonary care providers and patientsemerging

    They would use approved therapies for fibrotic lung disease and related indications.

Rein Therapeutics is headquartered in the United States and conducts most of its development and corporate activities...

  • •United States is the corporate base and a core clinical market
  • •FDA oversight is central to U.S. trial progression
  • •Australia is used for trial activation and patient enrollment
  • •United Kingdom sites support international clinical development
  • •Europe provides additional trial access and diversification

The company’s strategy is to advance LTI-03 and LTI-01 through preclinical and clinical development while expanding its...

01
Advance LTI-03 clinical developmentshort-term

LTI-03 is the lead asset and the main driver of future value creation.

02
Expand and diversify the pipelinemedium-term

Additional candidates reduce dependence on a single program and broaden optionality.

03
Maintain external development infrastructureshort-term

Outsourced CRO, manufacturing, and regulatory support are essential to move programs forward.

The company faces high clinical and regulatory risk because its value depends on successful trial execution,...

critical

FDA clinical hold on LTI-03

The lead Phase 2 trial was placed on hold pending additional nonclinical work.

Scope
LTI-03 RENEW Phase 2 trial
Materiality
high
high

Clinical development failure

Drug candidates may not demonstrate safety, tolerability, or efficacy in humans.

Scope
LTI-03 and LTI-01
Materiality
high
high

Financing risk

The company needs external capital to fund trials, manufacturing, and operations.

Scope
Corporate liquidity and development programs
Materiality
high
medium

Third-party execution risk

Clinical and manufacturing work is outsourced and depends on vendor performance.

Scope
CROs, manufacturers, consultants
Materiality
medium
medium

Intellectual property and partnering risk

Value depends on protecting assets and maintaining collaboration or licensing options.

Scope
Pipeline assets and future commercialization
Materiality
medium
Research and development accruals
Can shift quarterly R&D expense materially
Clinical supply inventory and write-offs
Can create one-time expense spikes
Warrants and equity financing
Affects equity, earnings per share, and capital structure
Contingent consideration and partnering fees
Can affect other income, liabilities, or future cash flows

Inhibikase Therapeutics, Inc.

IKT · Biological Products, (No Diagnostic Substances)

BriaCell Therapeutics Corp.

BCTX · Pharmaceutical Preparations

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

UNITED THERAPEUTICS Corp

UTHR · Pharmaceutical Preparations

: 29/04/2026